MIDATECH PHARMA
Technologies | Sustained Release

Midatech’s sustained release technology platform (“Q-Sphera”) may enable active drug compounds to be manufactured with consistent precision and released into the body in a highly controlled manner over a prolonged period of time: potentially from a few days to up to six months.

The potential advantages of the sustained release drug delivery system over conventional dosage forms include:

Midatech’s Q-Sphera polymer microsphere platform is being developed to enable sustained release delivery solutions for peptide and small-molecule therapeutics through precise definition of the properties of polymer microparticles into which compounds can be incorporated. Microspheres are small, spherical particles that can be utilised as a time release drug capsule.

Midatech's Q-Sphera micro-fluidic technology allows the precise formulation and characterisation of the release of drugs over a predefined period from a few days up to three months. The manufacturing technology allows particles to be engineered with high precision and consistent size, alongside other key characteristics.

Q-Sphera can use a wide range of biomaterials to encapsulate drug candidates into micron sized particles (of diameter ~25μm). Long-acting treatment is achieved using formulations of biodegradable polymers (including polylactides) to control the release of API over a period of 3-6 months following a single injection. Monodisperse microspheres may be readily injected via minimally-invasive needles as fine as 30G. In formulating small molecules, biopharmaceuticals and PEGylated species, Midatech focuses on developing products that provide high drug loading, with minimal initial burst release, which is essential to the development of safe and effective therapies. This requires precise control over particle size, morphology and drug kinetics. This Midatech microsphere manufacturing enables emulsion-free synthesis with both product monodispersity and processing efficiency.

Markets of focus for such preparations include oncology, immunology, endocrinology, neuroscience, and ophthalmology. Sustained release programs are underway in:

Technologies
Sustained Release

Midatech’s sustained release technology platform (“Q-Sphera”) may enable active drug compounds to be manufactured with consistent precision and released into the body in a highly controlled manner over a prolonged period of time: potentially from a few days to up to six months.

The potential advantages of the sustained release drug delivery system over conventional dosage forms include:

Midatech’s Q-Sphera polymer microsphere platform is being developed to enable sustained release delivery solutions for peptide and small-molecule therapeutics through precise definition of the properties of polymer microparticles into which compounds can be incorporated. Microspheres are small, spherical particles that can be utilised as a time release drug capsule.

Midatech's Q-Sphera micro-fluidic technology allows the precise formulation and characterisation of the release of drugs over a predefined period from a few days up to three months. The manufacturing technology allows particles to be engineered with high precision and consistent size, alongside other key characteristics.

Q-Sphera can use a wide range of biomaterials to encapsulate drug candidates into micron sized particles (of diameter ~25μm). Long-acting treatment is achieved using formulations of biodegradable polymers (including polylactides) to control the release of API over a period of 3-6 months following a single injection. Monodisperse microspheres may be readily injected via minimally-invasive needles as fine as 30G. In formulating small molecules, biopharmaceuticals and PEGylated species, Midatech focuses on developing products that provide high drug loading, with minimal initial burst release, which is essential to the development of safe and effective therapies. This requires precise control over particle size, morphology and drug kinetics. This Midatech microsphere manufacturing enables emulsion-free synthesis with both product monodispersity and processing efficiency.

Markets of focus for such preparations include oncology, immunology, endocrinology, neuroscience, and ophthalmology. Sustained release programs are underway in:

© Copyright 2017 Midatech Pharma PLC